Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence

Journal of Substance Abuse Treatment

Volumn 34, Issue 4, 2008, Pages 378-390

  Pettinati, Helen M ^a   Kampman, Kyle M ^a   Lynch, Kevin G ^a   Suh, Jesse J ^a   Dackis, Charles A ^a   Oslin, David W ^a,b   O'Brien, Charles P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adverse events; Alcohol dependence; BRENDA; CBT; Cocaine dependence; Naltrexone

Indexed keywords

ALCOHOL; COCAINE; NALTREXONE; PLACEBO;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; PAIN; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SELF REPORT; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SEX FACTORS;

EID: 42949102001     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2007.05.011     Document Type: Article

References (73)

1. Alterman A.I., Brown L.S., Zaballero A., and McKay J.R. Interviewer severity ratings and composite scores of the ASI: A further look. Drug and Alcohol Dependence 34 (1994) 201-209
2. Andrews P. Cocaethylene toxicity. Journal of Addictive Diseases 16 (1997) 75-84
3. Anton R.F., Moak D.H., Latham P., Waid L.R., Myrick H., Voronin K., et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. Journal of Clinical Psychopharmacology 25 (2005) 349-357
4. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., and Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. American Journal of Psychiatry 156 (1999) 1758-1764
5. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association 295 (2006) 2003-2017
6. Bain G.T., and Kornetsky C. Naloxone attenuation of the effect of cocaine on rewarding brain stimulation. Life Science 40 (1987) 1119-1125
7. Berkley K.J. Sex differences in pain. Behavioral and Brain Sciences 20 (1997) 371-380
8. Brady K., Sonne S., Randall C., Adinoff B., and Malcolm R. Features of cocaine dependence with concurrent alcohol abuse. Drug and Alcohol Dependence 39 (1995) 69-71
9. Cami J., Farre M., Gonzalez M.L., Segura J., and de la Torre R. Cocaine metabolism in humans after use of alcohol. Clinical and research implications. Recent Developments in Alcoholism 14 (1998) 437-455
10. Carroll K., Rounsaville B., and Bryant K. Alcoholism in treatment seeking cocaine abusers: Clinical and prognostic significance. Journal of Studies on Alcoholism 54 (1993) 199-208
11. Carroll K.M. A cognitive-behavioral approach: Treating cocaine addiction (1998), National Institute on Drug Abuse, Rockville, MD
12. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry 61 (2004) 264-272
13. Corrigall W.A., and Coen K.M. Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology (Berl) 104 (1991) 167-170
14. Dackis C.A., and O'Brien C.P. Cocaine dependence: A disease of the brain's reward centers. Journal of Substance Abuse Treatment 21 (2001) 111-117
15. Dackis C.A., and O'Brien C.P. The neurobiology of addiction. In: Asbury A., Goadsby P., and McArthur J. (Eds). Diseases of the nervous system. 3rd ed. (2002), Cambridge University Press, Cambridge 431-444
16. Dackis C.A., and O' Brien C.P. Glutamatergic agents for cocaine dependence. Annals of New York Academy of Sciences 103 (2003) 1-18
17. Dackis C.A., and O'Brien C.P. The neurobiology of alcoholism. In: Soires J.C., and Gershon S. (Eds). Handbook of medical psychiatry (2003), Marcel Dekker, New York 563-580
18. Diggle P., Heagerty P., Liang K., and Zeger S. Analysis of longitudinal data (2002), Oxford University Press, Oxford
19. Ehrman R.N., and Robbins S.J. Reliability and validity of 6-month timeline reports of cocaine and heroin use in a methadone population. Journal of Consulting and Clinical Psychology 62 (1994) 843-850
20. Fals-Stewart W., O'Farrell T.J., Freitas T.T., McFarlin S.K., and Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. Journal of Consulting and Clinical Psychology 68 (2000) 134-144
21. Farre M., de la Torre R., Llorente M., Lamas X., Ugena B., Segura J., et al. Alcohol and cocaine interactions in humans. Journal of Pharmacology and Experimental Therapeutics 266 (1993) 1364-1373
22. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I disorders-Subject edition (SCID-I/P, version 2.0) (1996), Biometrics Research Department New York State Psychiatric Institute, New York, NY
23. Gandhi M., Aweeka F., Greenblatt R.M., and Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. Annual Review of Pharmacology and Toxicology 44 (2004) 499-523
24. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. Journal of the American Medical Association 293 (2005) 1617-1625
25. Heil S.H., Badger G.J., and Higgins S.T. Alcohol dependence among cocaine-dependent outpatients: Demographics, drug use, treatment outcome and other characteristics. Journal of Studies on Alcohol 62 (2001) 14-22
26. Hernandez-Avila C.A., Song C., Kuo L., Tennen H., Armeli S., and Kranzler H.R. Targeted versus daily naltrexone: Secondary analysis of effects on average daily drinking. Alcoholism: Clinical and Experimental Research 30 (2006) 860-865
27. Hersh D., Mulgrew C.L., Van Kirk J., and Kranzler H.R. The validity of self-reported cocaine use in two groups of cocaine abusers. Journal of Consulting and Clinical Psychology 67 (1999) 37-42
28. Hersh D., Van Kirk J.R., and Kranzler H.R. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl) 139 (1998) 44-52
29. Higgins S.T., Budney A.J., Bickel W.K., Foerg F.E., and Badger G.J. Alcohol dependence and simultaneous cocaine and alcohol use in cocaine-dependent patients. Journal of Addictive Diseases 13 (1994) 177-189
30. Jatlow P., Elsworth J.D., Bradberry C.W., Winger G., Taylor J.R., Russell R., et al. Cocaethylene: A neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Life Science 48 (1991) 1787-1794
31. Johnson B.A., O'Malley S.S., Ciraulo D.A., Roache J.D., Chambers R.A., Sarid-Segal O., et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. Journal of Clinical Psychopharmacology 23 (2003) 281-293
32. Katz J.L., Terry P., and Witkin J.M. Comparative behavioral pharmacology and toxicology of cocaine and its ethanol-derived metabolite, cocaine ethyl-ester (cocaethylene). Life Science 50 (1992) 1351-1361
33. Kiefer F., Jahn H., and Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry 38 (2005) 184-186
34. King A.C., Volpicelli J.R., Frazer A., and O'Brien C.P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) 129 (1997) 15-22
35. Kiyatkin E.A., and Brown P.L. Naloxone depresses cocaine self-administration and delays its initiation on the following day. Neuroreport 14 (2003) 251-255
36. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., and Rosenheck R.A. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 345 (2001) 1734-1739
37. Lee O.Y., Mayer E.A., Schmulson M., Chang L., and Naliboff B. Gender-related differences in IBS symptoms. American Journal of Gastroenterology 96 (2001) 2184-2193
38. Maisto S.A., Sobell L.C., and Sobell M.B. Comparison of alcoholics' self-reports of drinking behavior with reports of collateral informants. Journal of Consulting and Clinical Psychology 47 (1979) 106-112
39. Marlatt G.A., and Gordon J.R. Relapse prevention (1985), Guilford Press, New York, NY
40. McCance-Katz E.F., Kosten T.R., and Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone-A multiple-dose study. Biological Psychiatry 44 (1998) 250-259
41. McCance-Katz E.F., Price L.H., McDougle C.J., Kosten T.R., Black J.E., and Jatlow P.I. Concurrent cocaine-ethanol ingestion in humans: Pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology (Berl) 111 (1993) 39-46
42. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 9 (1992) 199-213
43. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., et al. New data from the Addiction Severity Index. Reliability and validity in three centers. Journal of Nervous and Mental Disease 173 (1985) 412-423
44. Mengis M.M., Maude-Griffin P.M., Delucchi K., and Hall S.M. Alcohol use affects the outcome of treatment for cocaine abuse. American Journal on Addictions 11 (2002) 219-227
45. Miller N.S., Gold M.S., Belkin B.M., and Klahr A.L. The diagnosis of alcohol and cannabis dependence in cocaine dependents and alcohol dependence in their families. British Journal of Addiction 84 (1989) 1491-1498
46. Nich C., McCance-Katz E.F., Petrakis I.L., Cubells J.F., Rounsaville B.J., and Carroll K.M. Sex differences in cocaine-dependent individuals' response to disulfiram treatment. Addictive Behaviors 29 (2004) 1123-1128
47. O'Brien C.P., Volpicelli L.A., and Volpicelli J.R. Naltrexone in the treatment of alcoholism: A clinical review. Alcohol 13 (1996) 35-39
48. Olive M.F., Koenig H.N., Nannini M.A., and Hodge C.W. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. Journal of Neuroscience 21 (2001) RC184
49. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., and Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Archives of General Psychiatry 49 (1992) 881-887
50. O'Malley S.S., Krishnan-Sarin S., Farren C., and O'Connor P.G. Naltrexone-induced nausea in patients treated for alcohol dependence: Clinical predictors and evidence for opioid-mediated effects. Journal of Clinical Psychopharmacology 20 (2000) 69-76
51. O'Malley S.S., Rounsaville B.J., Farren C., Namkoong K., Wu R., Robinson J., et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs. specialty care: A nested sequence of 3 randomized trials. Archives of Internal Medicine 163 (2003) 1695-1704
52. Oncken C., Van Kirk J., and Kranzler H.R. Adverse effects of oral naltrexone: Analysis of data from two clinical trials. Psychopharmacology 154 (2001) 397-402
53. Oslin D.W., Pettinati H.M., Volpicelli J.R., Wolf A.L., Kampman K.M., and O'Brien C.P. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. Journal of Substance Abuse Treatment 16 (1999) 163-167
54. Pennings E.J., Leccese A.P., and Wolff F.A. Effects of concurrent use of alcohol and cocaine. Addiction 97 (2002) 773-783
55. Perez-Reyes M., and Jeffcoat A.R. Ethanol/cocaine interaction: Cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects. Life Science 51 (1992) 553-563
56. Pettinati H., Volpicelli J., Pierce J., and O'Brien C. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases 19 (2000) 71-83
57. Pettinati H.M., Dundon W., and Lipkin C. Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence. American Journal on Addictions 13 (2004) 236-247
58. Pettinati H.M., Weiss R.D., Dundon W., Miller W.R., Donovan D., Ernst D.B., et al. A structured approach to medical management: A psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. Journal of Studies on Alcohol Supplement (2005) 170-178 (discussion, 168-179)
59. Rabkin J.G., Markowitz J.S., Ocepek-Welikson K., and Wager S.S. General versus systematic inquiry about emergent clinical events with SAFTEE: Implications for clinical research. Journal of Clinical Psychopharmacology 12 (1992) 3-10
60. Rohsenow D.J., Colby S.M., Monti P.M., Swift R.M., Martin R.A., Mueller T.I., et al. Predictors of compliance with naltrexone among alcoholics. Alcoholism Clinical and Experimental Research 24 (2000) 1542-1549
61. Schmitz J.M., Stotts A.L., Rhoades H.M., and Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addictive Behaviors 26 (2001) 167-180
62. Schmitz J.M., Stotts A.L., Sayre S.L., DeLaune K.A., and Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. American Journal on Addictions 13 (2004) 333-341
63. Shoptaw S., Kintaudi P.C., Charuvastra C., and Ling W. A screening trial of amantadine as a medication for cocaine dependence. Drug and Alcohol Dependence 66 (2002) 217-224
64. Sobell L.C., Maisto S.A., Sobell M.B., and Cooper A.M. Reliability of alcohol abusers' self-reports of drinking behavior. Behaviour Research and Therapy 17 (1979) 157-160
65. Suh J.J., Pettinati H.M., Kampman K.M., Lynch K.G., and O'Brien C.P. Gender differences in predicting treatment retention with high-dose naltrexone. Paper presented at the 67th Annual Scientific Meeting of The College on Problems of Drug Dependence, Orlando, FL (2005)
66. Volpicelli J., Alterman A., Hayashida M., Muentz L., and O'Brien C. Naltrexone and the treatment of alcohol dependence. In: Reid D. (Ed). Opioids, bulimia and alcoholism (1990), Springer-Verlag, New York 195-214
67. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49 (1992) 876-880
68. Volpicelli J.R., Pettinati H.M., McLellan A.T., and O'Brien C.P. Combining medication and psychosocial treatments for addictions: The BRENDA approach (2001), Guilford Press, New York, NY
69. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., and Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. Journal of Pharmacology and Experimental Therapeutics 279 (1996) 524-538
70. Wilson L.D., Jeromin J., Garvey L., and Dorbandt A. Cocaine, ethanol, and cocaethylene cardiotoxicity in an animal model of cocaine and ethanol abuse. Academic Emergency Medicine 8 (2001) 211-222
71. Wise R.A. Neurobiology of addiction. Current Opinion in Neurobiology 6 (1996) 243-251
72. Wong C.J., Badger G.J., Sigmon S.C., and Higgins S.T. Examining possible gender differences among cocaine-dependent outpatients. Experimental and Clinical Psychopharmacology 10 (2002) 316-323
73. Zanis D.A., McLellan A.T., and Randall M. Can you trust patient self-reports of drug use during treatment?. Drug and Alcohol Dependence 35 (1994) 127-132